Botulinum toxin A intravesicular - AbbVie/UroGen
Alternative Names: BotuGel™; TCgel mixed with botulinium toxin ALatest Information Update: 04 Mar 2021
Price :
$50 *
At a glance
- Originator TheraCoat
- Developer UroGen Pharma
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein inhibitors; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Interstitial cystitis; Overactive bladder
Most Recent Events
- 04 Mar 2021 No development reported - Phase-II for Overactive bladder in Israel (Intravesicular) (UroGen Pharma pipeline, March 2021)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 27 Dec 2018 9257465: no updates